A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

NCT03164915 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

BIOLOGICAL: LIV-GAMMA SN Inj.

Sponsor

SK Plasma Co., Ltd.